semaglutide cardiovascular outcomes 2025 news A Lancet analysis of the SELECT trial concluded that reduced major adverse events by 20% in adults with overweight or obesity, regardless of how much weight patients actually lost Semaglutide cardiovascular outcomes align more

NNMT methylates nicotinamide using SAM as a methyl donor

Since then, more than 3,300 GLP-1 stomach paralysis lawsuits have been filed in federal courts nationwide

Unlock a brighter future by cultivating a culture of wellness that fuels your health, productivity, and motivation by making informed choices, you can mitigate the risk of weight-related issues, diabetes, and so much more, all while fostering a positive relationship with food and your overall well-being

Tirzepatide (Mounjaro/Zepbound) may cause slightly more GI side effects overall because it targets two receptors (GLP-1 + GIP), but individual responses vary